-
Fierce Biotech3 months ago
FDA approves Denali’s Hunter syndrome drug, handing rare disease community a win
The FDA has approved Denali Therapeutics’ enzyme replacement therapy for a genetic lysosomal storage disease after a string of high-profile rejections for rare disease candidates.
-
GEN – Genetic Engineering & Biotechnology News3 months agoXaira’s First Virtual Cell Model Is Largest To-Date, Toward Complex Biology
Billion dollar-backed AI drug developer, Xaira Therapeutics, has recently released the largest virtual cell model to-date to predict how cells respond to genetic perturbations in unseen biological contexts. The team asserts that accurately predicting transcriptome-level effects is a...
-
STAT News – Biotech3 months agoSTAT+: Eli Lilly and the ‘societal obligation’ of GLP-1s
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We’ve got more...
-
STAT News – Biotech3 months agoSTAT+: Pharmalittle: We’re reading about a Merck acquisition, the rise of former Loxo execs at Lilly, and more
Hi there, and happy Wednesday from STAT’s London bureau, with Andrew Joseph here tag-teaming today’s edition with Mr. Pharmalot. We’re in the midst of those confusing...
-
STAT News – Biotech3 months agoHow to make emergency rooms safer for people with dementia
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning. Today’s the deadline for the White...
-
Endpoints News3 months ago
Microneedle vaccine patch company raises $50M for pivot to GLP-1 delivery
Fourteen years ago, a group of Harvard Business School students launched a startup called Vaxess Technologies with a goal to disrupt the vaccine industry by replacing...
-
Uncategorized3 months agoNew protein drugs could pave way for faster drug development
A new class of protein drugs have shown amenability to multiple isotopes, paving the way for faster radiopharmaceutical drug development. Biotechnology company Molecular Partners announced preclinical...
-
BioPharma Dive – AI / Data3 months agoMerck to buy Terns in $6.7B bet on a ‘differentiated’ leukemia drug
If consummated, the deal would hand Merck a treatment that could challenge Novartis’ fast-selling Scemblix. But the low purchase premium — which one analyst described as...
-
Uncategorized3 months agoGilead to advance first T cell engager for autoimmune diseases
Gilead Sciences has entered an agreement to acquire Ouro Medicines, a biotechnology company focused on developing T cell engager therapies for autoimmune diseases. The acquisition adds...
-
Uncategorized3 months ago‘Supercharged’ T cells could improve prostate cancer treatment
Scientists have engineered new ‘supercharged’ immune cells that could attack prostate cancer more effectively. Researchers at UCLA and Stanford Medicine researchers, in collaboration with scientists from the...
Beyond sunshine: Iberia’s biotech moment has arrived with developing capital networks
Laser‑Driven Phase Contrast Enhances Cryo‑EM Resolution of Small Proteins
